113 related articles for article (PubMed ID: 22669803)
21. Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
Brunton S; Davidson JA
Clin Ther; 2016 Mar; 38(3):582-94. PubMed ID: 26926319
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
Molina Vega M; Muñoz-Garach A; Tinahones FJ
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
[TBL] [Abstract][Full Text] [Related]
24. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR; Bethel MA; Mentz RJ; Thompson VP; Lokhnygina Y; Buse JB; Chan JC; Choi J; Gustavson SM; Iqbal N; Maggioni AP; Marso SP; Öhman P; Pagidipati NJ; Poulter N; Ramachandran A; Zinman B; Hernandez AF;
N Engl J Med; 2017 Sep; 377(13):1228-1239. PubMed ID: 28910237
[TBL] [Abstract][Full Text] [Related]
25. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
[TBL] [Abstract][Full Text] [Related]
27. Exenatide once weekly: opportunities in the primary care setting.
Davidson JA; Nikkel C; Grimm M
Postgrad Med; 2013 May; 125(3):68-78. PubMed ID: 23748508
[TBL] [Abstract][Full Text] [Related]
28. Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568.
Drugs R D; 2004; 5(1):35-40. PubMed ID: 14725490
[TBL] [Abstract][Full Text] [Related]
29. Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.
Grossman SS
Adv Ther; 2014 Mar; 31(3):247-63. PubMed ID: 24535624
[TBL] [Abstract][Full Text] [Related]
30. Exenatide once weekly in type 2 diabetes.
Scheen AJ
Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642
[No Abstract] [Full Text] [Related]
31. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
Best JH; Rubin RR; Peyrot M; Li Y; Yan P; Malloy J; Garrison LP
Diabetes Care; 2011 Feb; 34(2):314-9. PubMed ID: 21270189
[TBL] [Abstract][Full Text] [Related]
32. An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.
Crasto W; Khunti K; Davies MJ
Drugs Today (Barc); 2011 Nov; 47(11):839-56. PubMed ID: 22146227
[TBL] [Abstract][Full Text] [Related]
33. Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
Anderson ZL; Clements JN
JAAPA; 2014 Jun; 27(6):44-6. PubMed ID: 24853156
[TBL] [Abstract][Full Text] [Related]
34. Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
Prescrire Int; 2013 Jun; 22(139):151. PubMed ID: 23885352
[No Abstract] [Full Text] [Related]
35. Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site.
Shan SJ; Guo Y
Am J Dermatopathol; 2014 Jun; 36(6):510-2. PubMed ID: 24366197
[TBL] [Abstract][Full Text] [Related]
36. Exenatide as a novel weight loss modality in patients without diabetes.
Moreno JL; Willett KC; Desilets AR
Ann Pharmacother; 2012 Dec; 46(12):1700-6. PubMed ID: 23191935
[TBL] [Abstract][Full Text] [Related]
37. Long-acting preparations of exenatide.
Cai Y; Wei L; Ma L; Huang X; Tao A; Liu Z; Yuan W
Drug Des Devel Ther; 2013; 7():963-70. PubMed ID: 24039406
[TBL] [Abstract][Full Text] [Related]
38. Effect of renal impairment on the pharmacokinetics of exenatide.
Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
[TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
Cirincione B; Edwards J; Mager DE
AAPS J; 2017 Mar; 19(2):487-496. PubMed ID: 27896683
[TBL] [Abstract][Full Text] [Related]
40. Exenatide pharmacokinetics in healthy Chinese subjects.
Zhao X; Cui YM; Zhou Y; Zhang HL; Yeo KP; Linnebjerg H; Tham LS; Kothare P; Teng LL; Mace K; Soon D
Int J Clin Pharmacol Ther; 2008 Sep; 46(9):459-65. PubMed ID: 18793576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
